<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; approval</title>
	<atom:link href="http://www.tapanray.in/tag/approval/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>A Game-Changing Non-Covid Drug Approval In the Pandemic Milieu</title>
		<link>http://www.tapanray.in/a-game-changing-non-covid-drug-approval-in-the-pandemic-milieu/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-game-changing-non-covid-drug-approval-in-the-pandemic-milieu</link>
		<comments>http://www.tapanray.in/a-game-changing-non-covid-drug-approval-in-the-pandemic-milieu/#comments</comments>
		<pubDate>Mon, 11 Oct 2021 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[consumers]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[designation]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Glargine]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insuline]]></category>
		<category><![CDATA[interchangeable]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[milieu]]></category>
		<category><![CDATA[original]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Semglee]]></category>
		<category><![CDATA[superior]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10595</guid>
		<description><![CDATA[Amid high decibel deliberations on Covid-19 pandemic, something similar to groundbreaking happened &#8211; involving Biosimilar drugs, in just a couple of months ago. On July 28, 2021, in the Eldorado of the pharma industry, the US-FDA approved  the first ‘interchangeable’ biosimilar drug, &#8230; <a href="http://www.tapanray.in/a-game-changing-non-covid-drug-approval-in-the-pandemic-milieu/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-game-changing-non-covid-drug-approval-in-the-pandemic-milieu/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Prescription Digital Therapy Now A Reality</title>
		<link>http://www.tapanray.in/prescription-digital-therapy-now-a-reality/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=prescription-digital-therapy-now-a-reality</link>
		<comments>http://www.tapanray.in/prescription-digital-therapy-now-a-reality/#comments</comments>
		<pubDate>Mon, 07 May 2018 00:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2]]></category>
		<category><![CDATA[3]]></category>
		<category><![CDATA[app]]></category>
		<category><![CDATA[Apple]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[chronic]]></category>
		<category><![CDATA[cognition]]></category>
		<category><![CDATA[diabetic]]></category>
		<category><![CDATA[digiceuticals]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[disorder]]></category>
		<category><![CDATA[Epilepsy]]></category>
		<category><![CDATA[fitness]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MDD]]></category>
		<category><![CDATA[mood]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Parkinson's]]></category>
		<category><![CDATA[Pear]]></category>
		<category><![CDATA[Pears]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reality]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[reSet]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[scope]]></category>
		<category><![CDATA[seizures]]></category>
		<category><![CDATA[Substance]]></category>
		<category><![CDATA[Takeda]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Therapeutics]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[use]]></category>
		<category><![CDATA[version]]></category>
		<category><![CDATA[Watch]]></category>
		<category><![CDATA[wealthy]]></category>
		<category><![CDATA[wearable]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8981</guid>
		<description><![CDATA[The pursuit of offering ‘prescription digital therapeutics’ or ‘digiceuticals’ by Big Pharma, to ensure better clinical outcomes for patients, has apparently come to fruition now. On April 18, 2018, by a media release, Novartis announced that the Sandoz Division of the Company &#8230; <a href="http://www.tapanray.in/prescription-digital-therapy-now-a-reality/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/prescription-digital-therapy-now-a-reality/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Improving Patient Access To Biosimilar Drugs: Two Key Barriers</title>
		<link>http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=improving-patient-access-to-biosimilar-drugs-two-key-barriers</link>
		<comments>http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/#comments</comments>
		<pubDate>Mon, 31 Jul 2017 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[evidence]]></category>
		<category><![CDATA[framework]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[interchangeable]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[middle]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[path]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8334</guid>
		<description><![CDATA[Novel biologic medicines have unlocked a new frontier offering more effective treatment for a host of chronic and life-threatening diseases, such as varieties of cancer, rheumatoid arthritis and diabetes, to name just a few. However, these drugs being hugely expensive, &#8230; <a href="http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Stem Cell Therapy in India: A Potential Game Changer in Disease Treatment</title>
		<link>http://www.tapanray.in/stem-cell-therapy-in-india-a-potential-game-changer-in-disease-treatment/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=stem-cell-therapy-in-india-a-potential-game-changer-in-disease-treatment</link>
		<comments>http://www.tapanray.in/stem-cell-therapy-in-india-a-potential-game-changer-in-disease-treatment/#comments</comments>
		<pubDate>Mon, 27 Feb 2017 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[adult]]></category>
		<category><![CDATA[Alzheimer's]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[banking]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[blood]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cell]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[cord]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[leukemia]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[multiple]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[sclerosis]]></category>
		<category><![CDATA[sources]]></category>
		<category><![CDATA[stem]]></category>
		<category><![CDATA[stem cell-based]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[types]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8111</guid>
		<description><![CDATA[Stem Cells (SC) offer an incredible potential to instill a new lease of life virtually to any organ of the human body, bringing them back to the pre-disease state through its own biological repair mechanism. Intensive research initiatives are on &#8230; <a href="http://www.tapanray.in/stem-cell-therapy-in-india-a-potential-game-changer-in-disease-treatment/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/stem-cell-therapy-in-india-a-potential-game-changer-in-disease-treatment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Curious Conundrum of New Drugs Approval Process</title>
		<link>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-curious-conundrum-of-new-drugs-approval-process</link>
		<comments>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/#comments</comments>
		<pubDate>Mon, 18 Jan 2016 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Alatrofloxacin]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[Aprotinin]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[CDC]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Cochrane]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[curious]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[Drotrecogin alfa]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Economist]]></category>
		<category><![CDATA[EFPIA]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[full]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[International]]></category>
		<category><![CDATA[London]]></category>
		<category><![CDATA[Lumiracoxib]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Matthew Herder]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Propoxyphene]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[registry]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Rofecoxib]]></category>
		<category><![CDATA[Rosiglitazone]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Sibutramine]]></category>
		<category><![CDATA[Tamiflu]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tegaserod]]></category>
		<category><![CDATA[Tetrazepam]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Vioxx]]></category>
		<category><![CDATA[W.H.O]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7360</guid>
		<description><![CDATA[Fathoming the details of just a short span of time, not going beyond the last 10 years, I find from the published data that many new drugs, such as, Alatrofloxacin, Aprotinin, Drotrecogin alfa, Lumiracoxib, Propoxyphene, Rofecoxib, Rosiglitazone, Sibutramine, Tegaserod, Tetrazepam, were &#8230; <a href="http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Outlook 2015: A Glimpse Of Some Drivers and Barriers</title>
		<link>http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers</link>
		<comments>http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/#comments</comments>
		<pubDate>Mon, 05 Jan 2015 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[exports]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Nadda]]></category>
		<category><![CDATA[outlook]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6291</guid>
		<description><![CDATA[Looking ahead, the brand new year 2015 appears quite interesting to me both from the global and also from the local pharmaceutical industry perspective. In this article I shall try to give a glimpse of some of the important drivers &#8230; <a href="http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Beyond &#8216;The Magic Moment&#8217; of New Drug Marketing Approval</title>
		<link>http://www.tapanray.in/beyond-the-magic-moment-of-new-drug-marketing-approval/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=beyond-the-magic-moment-of-new-drug-marketing-approval</link>
		<comments>http://www.tapanray.in/beyond-the-magic-moment-of-new-drug-marketing-approval/#comments</comments>
		<pubDate>Mon, 24 Jun 2013 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[adaptive]]></category>
		<category><![CDATA[Agency]]></category>
		<category><![CDATA[AL]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[focused]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[ingredient]]></category>
		<category><![CDATA[Jangle]]></category>
		<category><![CDATA[magic]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Missing]]></category>
		<category><![CDATA[moment]]></category>
		<category><![CDATA[multiple]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PhaseIV]]></category>
		<category><![CDATA[pst]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[reimbursement]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[sclerosis]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[surveillance]]></category>
		<category><![CDATA[Tacfidera]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[uncontrolled]]></category>
		<category><![CDATA[Union]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2394</guid>
		<description><![CDATA[“Uncontrolled clinical trials are causing havoc to human life. There are so many legal and ethical issues involved with clinical trials and the government has not done anything so far.” This is exactly what the Supreme Court of India observed &#8230; <a href="http://www.tapanray.in/beyond-the-magic-moment-of-new-drug-marketing-approval/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/beyond-the-magic-moment-of-new-drug-marketing-approval/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patented Drugs’ Pricing: Apprehensive Voices Could Turn into a Self-Defeating Prophecy</title>
		<link>http://www.tapanray.in/patented-drugs-pricing-apprehensive-voices-could-turn-into-a-self-defeating-prophecy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patented-drugs-pricing-apprehensive-voices-could-turn-into-a-self-defeating-prophecy</link>
		<comments>http://www.tapanray.in/patented-drugs-pricing-apprehensive-voices-could-turn-into-a-self-defeating-prophecy/#comments</comments>
		<pubDate>Mon, 04 Mar 2013 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[apprehensive]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[Australia]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[capita]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[CIPI]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[FICCI]]></category>
		<category><![CDATA[FOPE]]></category>
		<category><![CDATA[gandhi]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[IDMA]]></category>
		<category><![CDATA[IIT]]></category>
		<category><![CDATA[income]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IPA]]></category>
		<category><![CDATA[Kharagpur]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MSF]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[NewZealand]]></category>
		<category><![CDATA[NGO]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[parity]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[PCPD]]></category>
		<category><![CDATA[per]]></category>
		<category><![CDATA[power]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[purchasing]]></category>
		<category><![CDATA[rajiv]]></category>
		<category><![CDATA[ratio]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[support]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[UK]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2016</guid>
		<description><![CDATA[On February 21, 2013, the Department of Pharmaceuticals in a communication to the stakeholders announced that the committee to examine the issues of ‘Price Negotiations for Patented Drugs’ has since submitted its report to the Department. Simultaneously the stakeholders were &#8230; <a href="http://www.tapanray.in/patented-drugs-pricing-apprehensive-voices-could-turn-into-a-self-defeating-prophecy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patented-drugs-pricing-apprehensive-voices-could-turn-into-a-self-defeating-prophecy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patients’ Safety, regulatory approval of Biosimilar Drugs in India and WHO Biosimilar guidelines</title>
		<link>http://www.tapanray.in/patients-safety-regulatory-approval-of-biosimilar-drugs-in-india-and-who-biosimilar-guidelines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patients-safety-regulatory-approval-of-biosimilar-drugs-in-india-and-who-biosimilar-guidelines</link>
		<comments>http://www.tapanray.in/patients-safety-regulatory-approval-of-biosimilar-drugs-in-india-and-who-biosimilar-guidelines/#comments</comments>
		<pubDate>Mon, 09 Aug 2010 00:30:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[DBT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MoH]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=390</guid>
		<description><![CDATA[Biopharmaceutical drugs are broadly defined as: ”Those medicines produced using a living system or genetically modified organism. These drugs are different from traditional chemical medicines in many ways. Size of the molecule is one of the most obvious distinctions: the &#8230; <a href="http://www.tapanray.in/patients-safety-regulatory-approval-of-biosimilar-drugs-in-india-and-who-biosimilar-guidelines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patients-safety-regulatory-approval-of-biosimilar-drugs-in-india-and-who-biosimilar-guidelines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
